Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Polycystic Ovary Syndrome 12Prostatic Neoplasms 2Osteoporosis 2Neoplasm Metastasis 2Hyperandrogenism 2Vaginitis 1Triple Negative Breast Neoplasms 1Sexual Dysfunction, Physiological 1Neoplasms 1Infertility, Female 1Infertility 1Hot Flashes 1Estrogen Receptor Positive Breast Cancer 1Estrogen Levels Among Breast Cancer Patients 1Coronary Disease 1Cardiovascular Diseases 1Atrophic Vaginitis 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1Abortion, Spontaneous 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Estradiol × Clear all
NCT03941730 2026-05-12

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled 9 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡